These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 12684609

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients.
    Riedel M, Eich FX, Möller HJ.
    Eur Psychiatry; 2009 Apr; 24(3):149-53. PubMed ID: 19070995
    [Abstract] [Full Text] [Related]

  • 3. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study.
    Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y, Amisulpride Study Group.
    Neuropsychopharmacology; 2002 Dec; 27(6):1071-81. PubMed ID: 12464464
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group.
    Peuskens J, Bech P, Möller HJ, Bale R, Fleurot O, Rein W.
    Psychiatry Res; 1999 Nov 08; 88(2):107-17. PubMed ID: 10622347
    [Abstract] [Full Text] [Related]

  • 7. Amisulpride: a review of its efficacy in schizophrenia.
    Möller HJ.
    Acta Psychiatr Scand Suppl; 2000 Nov 08; 400():17-22. PubMed ID: 10823307
    [Abstract] [Full Text] [Related]

  • 8. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA, Levine SZ, Tanaka S, Goldberg Y, Samara M, Davis JM, Cipriani A, Leucht S.
    JAMA Psychiatry; 2015 Jan 08; 72(1):14-21. PubMed ID: 25372935
    [Abstract] [Full Text] [Related]

  • 9. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies.
    Freeman HL.
    Int Clin Psychopharmacol; 1997 May 08; 12 Suppl 2():S11-7. PubMed ID: 9218163
    [Abstract] [Full Text] [Related]

  • 10. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group.
    Danion JM, Rein W, Fleurot O.
    Am J Psychiatry; 1999 Apr 08; 156(4):610-6. PubMed ID: 10200742
    [Abstract] [Full Text] [Related]

  • 11. Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study.
    Lin CH, Wang FC, Lin SC, Huang YH, Chen CC, Lane HY.
    Int Clin Psychopharmacol; 2013 Sep 08; 28(5):267-74. PubMed ID: 23778382
    [Abstract] [Full Text] [Related]

  • 12. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.
    Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G.
    Pharmacopsychiatry; 2008 Jan 08; 41(1):24-8. PubMed ID: 18203048
    [Abstract] [Full Text] [Related]

  • 13. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.
    Leucht S, Pitschel-Walz G, Engel RR, Kissling W.
    Am J Psychiatry; 2002 Feb 08; 159(2):180-90. PubMed ID: 11823257
    [Abstract] [Full Text] [Related]

  • 14. [Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses].
    Chabannes JP, Pelissolo A, Farah S, Gerard D.
    Encephale; 1998 Feb 08; 24(4):386-92. PubMed ID: 9809244
    [Abstract] [Full Text] [Related]

  • 15. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia.
    Mortimer A, Martin S, Lôo H, Peuskens J, SOLIANOL Sudy Group.
    Int Clin Psychopharmacol; 2004 Mar 08; 19(2):63-9. PubMed ID: 15076013
    [Abstract] [Full Text] [Related]

  • 16. Spotlight on amisulpride in schizophrenia.
    Curran MP, Perry CM.
    CNS Drugs; 2002 Mar 08; 16(3):207-11. PubMed ID: 11888341
    [Abstract] [Full Text] [Related]

  • 17. Practical issues with amisulpride in the management of patients with schizophrenia.
    Pani L, Villagrán JM, Kontaxakis VP, Alptekin K.
    Clin Drug Investig; 2008 Mar 08; 28(8):465-77. PubMed ID: 18598092
    [Abstract] [Full Text] [Related]

  • 18. Amisulpride: progress and outcomes.
    Lecrubier Y.
    Curr Med Res Opin; 2002 Mar 08; 18 Suppl 3():s18-22. PubMed ID: 12418608
    [Abstract] [Full Text] [Related]

  • 19. Augmentation with amisulpride for schizophrenic patients non-responsive to risperidone monotherapy.
    Toledo-Romero F, Molina JD, López-Rodríguez E, Amorin-Díaz M, Muñoz Algar MJ, Aparicio-Castro E.
    Pharmacopsychiatry; 2015 Mar 08; 48(2):51-7. PubMed ID: 25402816
    [Abstract] [Full Text] [Related]

  • 20. A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia.
    Lee SJ, Lee JH, Jung SW, Koo BH, Choi TY, Lee KH.
    Clin Drug Investig; 2012 Nov 08; 32(11):735-45. PubMed ID: 23018281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.